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Myasthenia Gravis
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Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular disease manifested 
by the weakness and fatigue in skeletal muscles of the face and extremities. 
Transient neonatal myasthenia gravis is an uncommon type of MG affecting 
the newborns with mothers who suffer from the disorder or specific circulat-
ing autoantibodies. In most cases, the intensity of transient neonatal MG is not 
associated with the mothers’ condition but rather with maternal antibody titers. 
The symptoms of transient neonatal MG are hypotonia, feeding difficulties, 
weak cry, facial diplegia, and breathing difficulties in the affected newborns. The 
disease is connected to the passive transplacental transfer of anti-acetylcholine 
receptor antibodies (anti-AChR) or antimuscle-specific tyrosine kinase antibodies 
(anti-MuSK) from the affected mother to the infant. The postsynaptic neuro-
muscular junction is damaged by the circulation of autoimmune antibodies, and 
the antibodies directed against fetal AChR are responsible for the form of fetal 
onset. Monitoring of these newborns is necessary in the first 7 days upon birth, 
since during this period of life, TNM symptoms can be detected, especially on the 
second day. In pregnancy period, myasthenia gravis symptoms may vary and they 
frequently worsen, sometimes leading to premature delivery.
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1. Introduction
Myasthenia gravis (MG) is a chronic progressive disease which is mani-
fested in weakness and tiredness of skeletal muscles as most typical symptoms. 
Neuromuscular transmission defects are responsible for MG onset [1].
The expression “myasthenia gravis” is of Latin origin, where “myasthenia” 
means “muscle weakness” and “gravis” means “serious” or “heavy.” The first report 
on MG was recorded in 1672 by Thomas Willis (1621–1675), a doctor from England 
whose main area of research was the nervous system [2].
Although patients suffering from myasthenia gravis do not experience any 
changes in the nervous and muscular systems, this disease causes a disorder in the 
transmission of the impulse from the nerve to the muscle, resulting in muscle weak-
ness which is a typical symptom of neurological diseases. One of the most recogniz-
able signals of this disease is the fluctuating weakness in the eyes, bulbar, limbs, and 
respiratory muscles [3, 4].
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MG can be defined as a relatively rare autoimmune disorder, affecting approxi-
mately 2 out of every 100,000 people, and can develop at any age. In patients 
affected by MG, antibodies are formed against acetylcholine nicotinic postsynaptic 
receptors at the neuromuscular junction of skeletal muscles which leads to progres-
sive skeletal muscle weakness [5]. Myasthenia gravis usually affects female popula-
tion at the age ranging from 18 to 25, whereas male population is affected by this 
disease later in life, at the age ranging from 60 to 80 [6].
Depending on the affected skeletal muscle groups, myasthenia gravis is catego-
rized into several classes:
• Class I: Only ocular muscles are weakened with possible weakness of eye 
closure, while other muscles remain unaffected.
• Class II: Mild weakness of any muscle group is possible as well as ocular muscle 
weakness of any degree.
• Class IIa: Most commonly causes weakness in limb and axial muscles; occur-
rence of oropharyngeal muscle weakness is also possible.
• Class IIb: Usually affects either oropharyngeal or respiratory muscles, but it 
can affect both muscle groups as well; limb and/or axial muscles can also be 
involved.
• Class III: Mild weakness of any muscle group is possible as well as ocular 
muscle weakness of any degree.
• Class IIIa: Most commonly causes weakness in limb and axial muscles; occur-
rence of oropharyngeal muscle weakness is also possible.
• Class IIIb: Usually affects either oropharyngeal or respiratory muscles, but it 
can affect both muscle groups as well; limb and/or axial muscles can also be 
involved.
• Class IV: Severe weakness of any muscle group is possible as well as ocular 
muscle weakness of any degree.
• Class IVa: Most commonly causes weakness in limb and axial muscles; occur-
rence of oropharyngeal muscle weakness is also possible
• Class IVb: Usually affects either oropharyngeal or respiratory muscles, but it 
can affect both muscle groups as well; limb and/or axial muscles can also be 
involved; application of a feeding tube without intubation.
• Class V: Characterized by the necessity of intubation, with or without 
mechanical ventilation, with the exception of cases of its application in routine 
postoperative management [7].
2. Myasthenia gravis during pregnancy
Myasthenia gravis can affect the courses of pregnancy and delivery, and it 
also presents a risk factor for the neonates [8]. On the other hand, pregnancy can 
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intensify the symptoms of myasthenia which can lead to complications during 
pregnancy and require a modified treatment. Attention should be paid to ensure 
an optimal treatment and drug safety before conception. Myasthenia gravis can 
be transferred to neonates. However, neonatal myasthenia gravis is a treatable 
and transient disease [9]. MG is relatively frequent in the reproductive period of 
1/10,000 to 1/50,000 [10].
The clinical course of MG can be altered unpredictably, and in various ways 
by pregnancy and the previous pregnancy, experiences are not a reliable source of 
information on the possible clinical course of subsequent pregnancies [11, 12].
In pregnancy, respiratory function of the lungs is compromised for two reasons. 
Hypoventilation caused by respiratory muscle weakness, on the one side, and 
diaphragm elevation caused by fetus growth on the other side lead to the reduction 
of the lung capacity [13].
MG symptoms can be worsened by puerperal respiratory and urinary tract 
infections; in order to avoid further complications, a prompt diagnosis and ade-
quate antibiotic treatment of these infections is necessary during pregnancy [14].
It should be taken into consideration that the selected groups of antibiotics—for 
example, fluoroquinolones (such as moxifloxacin and ciprofloxacin), macrolides 
(such as azithromycin and erythromycin), and aminoglycosides (such as strepto-
mycin and gentamicin)—can aggravate muscle weakness caused by MG; therefore, 
these types of antibiotics should be avoided [15].
During pregnancy therapy administration has to be based on individual con-
ditions and symptoms regarding the groups of muscles affected by MG in each 
patient, bearing in mind the possible side effects and consequences on the fetus [16].
For the symptomatic treatment of myasthenia gravis in the period of preg-
nancy, acetylcholinesterase inhibitors can be chosen. In most cases of MG during 
pregnancy, immunosuppressant corticosteroids are effective and hence should be 
selected in accordance with the symptoms in specific cases of MG [17].
Occurrence of premature membrane rupture and preterm delivery were also 
reported in cases when patients were treated with high doses of corticosteroids. There 
are records on temporary increase of MG symptom severity triggered by the intro-
duction of corticosteroid therapy. Although the introduction of immunosuppressive 
drugs should be avoided before and during pregnancy, therapy reduction or discon-
tinuation bears the risk of triggering a myasthenic crisis or exacerbation in pregnant 
myasthenic women. In order to control the teratogenic risk to the fetus, immunosup-
pressive drug dosages have to be carefully balanced and individualized [18].
On the other hand, recent reports suggest that azathioprine (AZA) therapy has 
shown to be successful in treatments of MG during pregnancy and breastfeeding 
periods. Even though AZA is absorbed through the placenta, its negative effects on 
the fetus are relatively minor since the fetal liver is immature and lacks the enzyme 
responsible for the conversion of AZA into its active metabolites. Cyclosporine A 
treatment is not considered to be harmful during the period of pregnancy and breast-
feeding, but it can also trigger prematurity, spontaneous abortions, and insufficient 
birth weight at birth. Another drug, mycophenolate mofetil (MMF), is thought to be 
teratogenic, causing a clinical syndrome which includes hypoplastic nails, shortened 
fifth fingers, oral cleft, microtia, diaphragmatic hernia, and micrognathia [19].
MG rarely affects the first stage of delivery, mostly because in this stage smooth 
muscles are involved. However, in the second stage, the mother can experience 
fatigue due to the involvement the voluntary striated muscles [20].
In this stage of delivery, mothers frequently feel exhausted, which may involve 
myasthenic crisis; therefore, the obstetrician needs to be ready for an assisted vagi-
nal delivery if required (e.g., performing vacuum extraction or using forceps) [21].
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Since MG patients are particularly sensitive to a number of anesthetics, an anes-
thesiologist should be consulted at the beginning of the pregnancy. Both in vaginal 
and in surgical deliveries, epidural anesthesia not exceeding the tenth thoracic 
vertebra level is advisable in order to ensure an adequate analgesia. While amide-
type local anesthetic agents (such as lidocaine, mepivacaine, and bupivacaine) 
have no impact on myasthenia, ester-type drugs (e.g., benzocaine, tetracaine, 
and procaine) are not the drug of choice because of the risk of aggravation of the 
existing myasthenia. Nonsteroidal anti-inflammatory medications (e.g., ketorolac 
tromethamine) and paracetamol (acetaminophen) may be included to ease post-
partum or postoperative pain, while narcotic analgesic agents that can contribute to 
respiratory depression are to be avoided [22].
Although anti-acetylcholine therapy can be used safely by nursing mothers 
suffering from MG, it may exacerbate symptoms of transient neonatal myasthenia 
gravis (TNMG), since anti-acetylcholine receptor antibodies (AChR-Ab) are 
contained in breast milk [23, 24].
Glucocorticoids and AZA are also not contraindicated in myasthenic mothers, 
but a liver function test must be performed, and complete blood count must be 
monitored in the newborns breastfed by myasthenic mothers. However, in breast-
feeding mothers with MG, mycophenolate mofetil is contraindicated [23].
Taking care of the newborn can be particularly strenuous for myasthenic moth-
ers due to the lack of sleep at night and constant daily caring for the infant. These 
extreme efforts may worsen the clinical symptoms of MG. In cases where immuno-
suppressive therapy has to be initiated or restarted after giving birth, contraceptive 
counseling is strongly recommended. A carefully chosen contraceptive has to be 
prescribed a minimum of 1 month prior to the initiation of immunosuppressive 
therapy, and it should not be discontinued 6 months prior to a new pregnancy. A 
cyclic withdrawal of oral contraceptives has been reported to initiate worsening of 
MG symptoms. In such cases, continuous hormonal contraception or an intrauter-
ine device is more preferable [25].
3. Newborns by myasthenic mothers
Neonatal MG is typically triggered by an autoactivation of the immune system. 
The causative factor is not known, but the disorder may have a genetic defect, lead-
ing to congenital MG, or placental transmission of maternal antibodies, resulting in 
transient neonatal MG. TNM is a temporary condition caused by transplacental cir-
culation of mothers’ antibodies. It develops in 10–20% cases of infants with myas-
thenic mothers, due to transplacental circulation of mothers’ antibodies [26, 27].
In these infants general muscle weakness is noticeable together with deficient 
suck, lethargy, and breathing difficulty until the fourth day upon birth. These 
symptoms are considered to be the consequence of transplacental transfer of 
antibodies. However, this causative effect is somewhat unclear, since a close correla-
tion has neither been found between the severity of MG in mothers and existence 
of neonatal myasthenia nor between neonatal myasthenia gravis and maternal 
anti-AChR antibody titers. The correlation might be explained by the protective role 
of alpha-fetoprotein in neonatal myasthenia gravis, as alpha-fetoprotein has been 
proven to inhibit the binding of myasthenia gravis antibody to its receptor [28, 29].
Premature delivery occurs in approximately 35% of cases of mothers. The most 
common fetal abnormalities are pulmonary hypoplasia and arthrogryposis. Death 
from malformations attributable to myasthenia gravis has also been reported [30].
Although TNMG can potentially be a life-threatening condition, it can have 
excellent prognosis if it is timely identified and properly treated [31].
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Transient neonatal myasthenia gravis (TNMG) is a rare form of MG which 
affects the infants whose mothers have the disorder or specific circulating autoanti-
bodies [32].
There are cases in which the mother is asymptomatic. The level of severity is not 
necessarily connected with the mother’s condition but rather with maternal anti-
body titers. The onset is typically shown immediately after birth. The recognizable 
symptoms in infants affected by TNMG are hypotonia, feeding difficulties, weak 
cry, facial diplegia, and respiratory distress in the affected neonates. Most com-
monly, these symptoms recede gradually with the decrease in maternally derived 
antibodies. The risk of this disorder continues for the subsequent births. The 
exact risk factors for the condition are yet to be identified. If treated promptly, the 
symptoms resolve within 2 months upon birth [33, 34].
TNMG is connected to the passive transplacental transfer of anti-acetylcholine 
receptor antibodies (anti-AChR) or anti-muscle-specific tyrosine kinase antibodies 
(anti-MuSK) from the affected mother to the infant. The postsynaptic neuro-
muscular junction is damaged by the circulation of autoimmune antibodies, and 
the antibodies directed against fetal AChR are responsible for the form of fetal 
onset [35].
The pathogenic role of acetylcholine receptor (AChR) antibodies has not been 
precisely determined. Despite the fact that passive-transfer acetylcholine receptor 
(AChR) antibodies are identified in most of these neonates, only a small percentage 
of infants develop the symptoms. A biological marker for prenatal detection of this 
group of neonates has not been identified yet, but recent reports suggest that HLA 
typing can be used successfully for this purpose. Final diagnosis can be given when 
the therapy of acetylcholinesterase agents temporarily improves the neuromuscular 
transmission disorder. Serum AChR antibody titers behave in the same way as the 
maternal pattern.
Anticholinesterase agents and supportive management before breastfeeding are 
required in approximately 80% of cases. The symptoms disappear spontaneously in 
most cases [27, 36, 37].
4. Conclusion
Newborns of mothers with MG manifest clinical features of TNM relative 
to the phase of the mothers’ disease and transplacental transfer of antibodies 
to acetylcholine receptors throughout the placenta. These newborns need to be 
monitored until their seventh day of life, as TNM symptoms can be visible from 
birth to 7 days of life, though most commonly on the second day of life. The 
clinical course of myasthenia gravis during pregnancy is variable, with a signifi-
cant proportion of patients experiencing worsening of clinical symptoms and 
premature delivery.
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